William Blair & Company
DNTH icon

William Blair & Company’s Dianthus Therapeutics DNTH Stock Holding History

William Blair & Company’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53M Buy
18,281
+356
+2% +$20.6K ﹤0.01% 814
2025
Q4 		$739K Buy
17,925
+2,050
+13% +$79.5K ﹤0.01% 1018
2025
Q3 		$625K Buy
+15,875
New +$406K ﹤0.01% 1044

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

William Blair & Company's DNTH Position: Q1 2026 in Review

William Blair & Company increased its Dianthus Therapeutics (DNTH) stake by 2% in Q1 2026, buying an estimated $20.6K and bringing the position to 18,281 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #814.

William Blair & Company first reported a position in DNTH in Q3 2025 and has held it in 3 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • William Blair & Company held 18,281 shares of Dianthus Therapeutics worth $1.53M as of Q1 2026.
  • William Blair & Company bought 356 Dianthus Therapeutics shares in Q1 2026, an estimated $20.6K.
  • Dianthus Therapeutics made up ﹤0.01% of William Blair & Company's portfolio in Q1 2026, its #814 holding.
  • William Blair & Company first reported a position in Dianthus Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.